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Abstract
Background: Activated drotrecogin alfa (human activated protein C, rhAPC), is produced by
recombinant DNA technology, and purports to improve clinical outcomes by counteracting the
inflammatory and thrombotic consequences of severe sepsis. Controversy exists around the
clinical benefits of this drug and an updated economic study that considers this variability is needed.
Methods:  A systematic literature review was performed using Medline, Embase and the
International Network of Agencies for Health Technology Assessment (INAHTA) databases to
determine efficacy, safety and previous economic studies. Our economic model was populated with
systematic estimates of these parameters and with population life tables for longer term survival
information. Monte Carlo simulations were used to estimate the incremental cost-effectiveness
ratios (ICERs) and variance for the decision analytic models.
Results: Two randomized clinical trials (RCTS) of drotrecogin alfa in adults with severe sepsis and
8 previous economic studies were identified. Although associated with statistical heterogeneity, a
pooled analysis of the RCTs did not show a statistically significant 28-day mortality benefit for
drotrecogin alfa compared to placebo either for all patients (RR: 0.93, 95% CI: 0.69, 1.26) or those
at highest risk as measured by APACHE II ≥ 25 (RR: 0.90, 95% CI: 0.54, 1.49). Our economic
analysis based on the totality of the available clinical evidence suggests that the cost-effectiveness
of drotrecogin alfa is uncertain (< 59% probability that incremental cost-effectiveness ratio (ICER)
life year gained (LYG) ≤ $50,000/LYG) when applied to all patients with severe sepsis. The
economic attractiveness of this therapy improves when administered to those at highest risk as
assessed by APACHE II ≥ 25 (93% probability ICER ≤ $50,000/LYG) but these results are not
robust to different measures of disease severity.
Conclusion: The evidence supporting the clinical and economic attractiveness of drotrecogin alfa
is not conclusive and further research appears to be indicated.
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Background
Sepsis is a complex syndrome with protean etiologies
characterized by a systemic inflammatory and procoagu-
lant response to an infection, and is considered severe in
the presence of acute organ dysfunction [1]. Endogenous
protein C activation attempts to counteract these manifes-
tations of sepsis and drotrecogin alfa, a form of human
activated protein C produced by recombinant DNA tech-
niques [2] has been approved for the subgroup of patients
with severe sepsis and the highest risk of death [3-5].
Controversy has plagued this drug since its 2001 FDA
evenly divided approval vote [6,7]. This controversy ema-
nates from approval being based on a single randomized
controlled trial (RCT) (PROWESS) and particularly on
one subgroup analysis. Moreover concerns exist regarding
drotrecogin alfa's cost-effectiveness and the inconsistent
results observed in more recent studies. Several economic
analyses have nevertheless suggested that the drug may be
cost-effective but these early studies have generally not
considered the totality of the efficacy evidence now avail-
able. Therefore we performed a systematic review of all
published drotrecogin alfa evidence, as a prelude for an
updated economic analysis to assist in difficult resource
allocation decisions.
Methods
Literature search
A systematic literature search of RCTs and economic eval-
uations comparing drotrecogin alfa and placebo in adult
and pediatric patients published in English or French was
performed using Medline and Embase databases (search
(MeSH) terms: (Drotrecogin OR Activated protein C OR
Xigris) AND (Sepsis). The search included publications
until Dec 31 2006. The reference lists of the publications
identified were also searched for additional relevant pub-
lications.
Methods for economic analysis
Cost-effectiveness analysis ($/life year gained (LYG) was
performed using a decision-tree model (see Figure 1) and
a 20 year horizon, based on the approximate life-expect-
ancy of our base case patient population. Drotrecogin alfa
efficacy measures for our economic model were ascer-
tained, when possible, by combining RCTs results from
our systematic review in a random effects meta-analysis
(RevMan V 4.2, Cochrane Collaboration, Oxford, Eng-
land). Beta distributions for model parameters were
derived from this information.
Survival rates for the first 30 months from RCT(s) were
available for drotrecogin alfa and placebo from the
PROWESS study [8]. We assumed that this numerical dif-
ference in survival at 30 months persisted without any fur-
ther increases or decreases in long term survival. Long
term survival could be estimated from population life
tables, corrected for the higher mortality risk in sepsis
patients. Costs beyond three years were also considered to
be similar between the two groups. Separate models were
developed for the whole study population and the sub-
groups at highest risk of death. Complication rates were
taken from a pooled analysis using data available from the
RCTs.
Probabilistic sensitivity analyses using 10,000 Monte
Carlo simulations were used to estimate the incremental
cost-effectiveness ratios (ICERs) and variance (TreeAge
Pro 2007). The economic analyses were performed from
the public healthcare provider viewpoint. Multiple sensi-
tivity analyses were performed using a different clinical
outcome (quality-adjusted life-years (QALYs) with utili-
ties measured with the EuroQoL-5D questionnaire [9], as
well as varying time horizons and discount rates. Table 1
shows the parameters and characteristics of the models
employed. Costs are provided in 2006 US dollars.
The presence of overlapping distributions in the effective-
ness, i.e., non statistically significant or small differences
between two comparators, or even negative effectiveness,
results in instability in the calculation of ICERs and their
confidence intervals thereby rendering their interpreta-
tion difficult [10,11]. Therefore we have graphically pre-
sented the results from our probabilistic sensitivity
analyses in the cost-effectiveness plane as this shows the
proportion of simulations where drotrecogin alfa had a
higher effectiveness and/or cost compared to placebo.
Acceptability curves using net health benefits are also pre-
sented as this measure overcomes the difficulties in inter-
preting negative ICERs [12].
Simplified decision analytic model employed Figure 1
Simplified decision analytic model employed. *The 
individual survival probabilities between 28 days and 30 
months were included in the model but are not shown in this 
figure. A similar tree was used in the bleeding and non-bleed-
ing arms, and for the drotrecogin alfa and placebo arms (not 
shown). After the 30 months a Markov model was employed 
(determined by the node M).BMC Anesthesiology 2007, 7:5 http://www.biomedcentral.com/1471-2253/7/5
Page 3 of 11
(page number not for citation purposes)
Results
Systematic literature review
Our systematic literature search identified 2 adult rand-
omized, double-blind, placebo-controlled trials [13,14]
(see Table 2) with long-term results available only for one
[8]. Both RCTs were terminated prematurely, one for effi-
cacy [13] and the other for futility [14]. Although the dis-
ease severity criteria for these two trials were slightly
different, the pooling of these studies is justified since the
same disease entity is being studied with the same
research design using the same treatment protocol (see
Table 2). The pooled 28-day efficacy results are shown in
Figure 2. The totality of the available evidence indicates
no statistically significant 28-day mortality reduction for
drotrecogin alfa in patients with severe sepsis (RR, 0.93,
95% CI: 0.69, 1.26), even when stratified by disease sever-
ity (APACHE II ≥ 25, RR: 0.90, 95% CI: 0.54, 1.49).
Despite the relative homogeneity in the 2 populations,
there was presence of statistical heterogeneity in the over-
all results. However when the analyses were performed
using the number of failed organs as a measure of disease
severity or when in-hospital mortality was used as out-
come (Figure 3), there was no longer evidence of statisti-
cal heterogeneity between the two RCTs.
Survival beyond 28 days or hospital discharge has been
reported only for the PROWESS study [8]. No statistically
significant mortality differences were observed in follow-
up from 3 to 30 months in the whole cohort of patients
and most reported subgroup analyses [8] except for the
subgroup defined by an Acute Physiology and Chronic
Health Evaluation (APACHE) II [15] score ≥ 25 (30-
month survival: 45.6% vs 33.8% for drotrecogin alfa and
placebo respectively, p = 0.001) [8]. In contrast, in the
subgroup with ≥ 2 organ dysfunctions, which was the cri-
terion used by the regulatory agency of the European
Union to define higher disease severity [4], there was no
Table 1: Parameters used in our decision analytic models.
Parameter Base case Source Univariate Sensitivity analyses
Effectiveness measure Life-years gained Based on long-term survival Quality-adjusted life years 
(QALYs)
Groups All patients
APACHE II ≥ 25
--
Mean entry age 60 years PROWESS [13] and ADDRESS 
[14]
-
Life-expectancy for a 60-year 
old
Males: 20 years
Females: 24 years
Statistics Canada Life-tables[59] -
Time horizon 20 years Statistics Canada Life-tables [59] 30 months to 30 years
Discount rate 3% - 0, 5%
Perspective of the analyses Public health care provider - -
Survival rates (see Tables 4-6 
for details)
Short-term (28-days) PROWESS [13] and ADDRESS 
[14] RCTs
Probabilistic sensitivity analysis 
using a beta distribution defined by 
the point estimate and variance 
from RCTs for each group.
Mid-term (hospital discharge – 30 
months)
Long-term PROWESS [8] RCT
Long-term beyond 30 months Observational study in severe 
sepsis patients [40] and Canadian 
life table (2000–2002) [59] 
adjusted for a higher mortality in 
severe sepsis patients*
Complication rates 28-day bleeding rates PROWESS [13] and ADDRESS 
[14]
-
Resources included in the cost 
analyses**
Drug acquisition Pharmacy department MUHC -
Hospitalization for the sepsis 
episode
Canadian long-term observational 
study in severe sepsis patients [40]
Treatment complications Years 1–
3 follow-up healthcare treatment 
costs
* The lifetime annual survival rates in the general population were adjusted for a higher severity in severe sepsis patients according to the absolute 
difference in mortality between the age-specific survival in the general population (1.1% for a 63-year old) [59] and that of a 3-year Canadian long-
term observation study in severe sepsis patients (4.2% and 6.2% in all patients and those with APACHE II ≥ 25 respectively at 3 years, mean age at 
cohort entry: 61.1 years [40]).
** Costs associated with the severe sepsis episode incurred after three years were not available and were considered identical for the two groups.
Our cost analysis included direct costs such as hospitalization, emergency room visits, day-surgery, and physician charges [40].BMC Anesthesiology 2007, 7:5 http://www.biomedcentral.com/1471-2253/7/5
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Table 2: Characteristics of available adult RCTs
PROWESS [13] ADDRESS [14]
Inclusion criteria summary Severe sepsis ≥ 1 organ dysfunction* Severe sepsis ≥ 1 organ dysfunction* and low risk of 
death
Therapy initiation within 48 hours of first organ dysfunction Within 48 hours of first organ dysfunction
Active treatment 96 hour intravenous infusion of drotrecogin alfa (24 μg/
kg/hr)
96 hour intravenous infusion of drotrecogin alfa (24 μg/
kg/hr)
Placebo 96-hour intravenous infusion (0.9% NaCl) 96-hour intravenous infusion (0.9% NaCl)
Baseline characteristics Drotrecogin alfa Placebo Drotrecogin alfa Placebo
N N = 850 N = 840 N = 1333 N = 1307
Age, mean ± SD (years) 60.5 ± 17.2 60.6 ± 16.5 58.8 ± 16.8 58.6 ± 16.7
Male (%) 56.1% 58% 56.3% 58.5%
APACHE II score, mean ± 
SD
24.6 ± 7.6 25 ± 7.8 18.2 ± 5.8 18.2 ± 5.9
Mechanical ventilation (%) 73.3% 77.6% 56.3% 55.8%
Shock (%) 70.4% 71.7% NA NA
Use of any vasopressor (%) 71.8% 75.5% 47.9% 47.5%
≥ 2 organ dysfunctions (%) 74.6% 75.8% 34.5% 31.5%
Time from 1st organ 
dysfunction to study drug 
start (hours), mean ± SD
17.5 ± 12.8 17.4 ± 9.1 22.5 ± 13.6 22.6 ± 13.8
* Cardiovascular, renal, respiratory, hematologic, or unexplained metabolic acidosis
RCT = randomized controlled trial/SD = standard deviation
28-day mortality meta-analysis Figure 2
28-day mortality meta-analysis. Some of the numbers in the graph are approximations as they were derived from figures 
in the published studies.BMC Anesthesiology 2007, 7:5 http://www.biomedcentral.com/1471-2253/7/5
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statistically significant survival benefit with drotrecogin
alfa over placebo [8], the same in other subgroups.
Because of its antithrombotic and profibrinolytic effects,
bleeding complications may be anticipated with drotrec-
ogin alfa [16]. Among the RCTs identified, the PROWESS
reported 30 (3.5%) 28-day serious bleeding events with
drotrecogin alfa and 17 (2%) with placebo (p = 0.06), in
the ADDRESS study there were 51 (3.9%) and 28 (2.2%)
such events respectively (p = 0.01) [14]. Pooling these two
studies together using the inverse variance method
yielded a 3.7% (± 1.06) rate of 28-day serious bleeding
events with drotrecogin alfa and 2.1% (± 1.04) with pla-
cebo.
Despite only 2 RCTs, there were numerous secondary
publications [17-30] involving subgroup analyses based
on the PROWESS [13] trial. In addition 3 meta-analyses
[31-33], and 9 economic analyses [34-42] were identified
(Table 3). The calculated cost/life-year gained (LYG) for
all patients varied between $US 8,500 and $US 33,300
and was generally slightly lower for higher risk patients
(Table 3). However, most of these analyses modeled long
term results by assuming that the PROWESS 28-day mor-
tality results were sustained and durable which has been
shown to be incorrect (see above).
Current economic analysis
Our decision analytic model is shown in Figure 1 and the
parameter and cost estimates are given in Tables 4, 5, 6.
The totality of the evidence for all patients revealed con-
siderable overlapping of the survival estimates in treated
and placebo patients resulting in approximately 27% of
the simulations with a negative ICER (i.e. more expensive
but less effective) for drotrecogin alfa compared to pla-
cebo (see Figure 4). The model using APACHE II >= 25 as
a severity measure showed a lower chance, approximately
3%, of a negative ICER (Figure 5).
Due to this instability in ICERs, we have elected to con-
centrate on acceptability curves that show the propor-
tional benefit at varying willingness to pay (WTP)
thresholds. Figures 6 and 7 show the net benefits accepta-
bility curve obtained for all patients and those with
APACHE II ≥ 25 respectively. In the model for all patients,
there was a 48% chance that the ICER will be ≤ $30,000/
LYG, and 59% chance that it will be ≤ $50,000 (Figure 6).
Considering only those patients with APACHE II ≥ 25,
there is an 89% chance of an ICER ≤ $30,000/LYG, and a
93% chance of an ICER ≤ $50,000/LYG (Figure 7). Since
drotrecogin alfa had a higher cost compared to placebo
due to its acquisition costs, the drug was never the domi-
nant strategy (defined by a higher effectiveness and lower
costs) in our analyses. Table 7 presents the incremental
cost and life-years gained with drotrecogin alfa compared
to placebo in our models.
Sensitivity analyses using QALYs as the measure of effec-
tiveness did not change the results appreciably. Similar
results were obtained with varying time horizons (10–30
years) and discount rates (data not shown). Importantly
in the high risk group when defined by ≥ 2 organ system
failures the probability that the ICER for drotrecogin alfa
compared to placebo was ≤ $50,000 was only 52%, testi-
fying to the lack of robustness in this subgroup economic
analysis.
Discussion
Our systematic review identified 2 RCTs, 3 meta-analyses,
and 9 economic analyses comparing drotrecogin alfa and
placebo in adults. Our results question the short term sur-
vival benefit of drotrecogin alfa and are in agreement with
In-Hospital mortality meta-analysis Figure 3
In-Hospital mortality meta-analysis. Some of the numbers in the graph are approximations as they were derived from fig-
ures in the published studies.BMC Anesthesiology 2007, 7:5 http://www.biomedcentral.com/1471-2253/7/5
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Table 3: Summary of the economic studies identified in the literature (values in US$). Results in all patients and by severity subgroups 
when available, drotrecogin alfa compared to placebo
Study Country (year of 
publication)
Incremental Cost* Incremental * effectiveness 
(LYG)
ICER* All severe sepsis 
patients
ICER* Higher risk patients
Manns et al. [40]
Canada (2002)
- 0.38 LYG
0.76 LYG (APACHE II ≥ 
25)
$ 27,936/LYG $ 19,726/LYG (APACHE II 
≥ 25)
Neilson et al [39]
Germany (2003)
$10,533 (all patients)
$11,238 LYG (≥ 2 organ 
dysfunctions)
0.47 LYG
0.69 LYG (≥ 2 organ 
dysfunctions)
US$ 22,411/LYG (3% 
discounting)
$ 17,419/LYG (≥ 2 organ 
dysfunctions)
Angus et al. [41]
US (2003)
$16,000 (±4,200) (all 
patients)
0.48 LYG (SD 0.29) (all 
patients)
$ 33,300/LYG -
Betancourt et al [38]
US (2003)
$6,246 (all patients)
$6,246 (≥ 2 organ 
dysfunctions)
0.06 lives saved**
0.08 (≥ 2 organ 
dysfunctions)
$ 104,100/life saved** $78,075/life saved (≥ 2 
organ dysfunctions)**
Fowler et al. [34]
Canada (2003)
$10,745 (all patients)
$15,166 (APACHE ≥ 25)
0.68 LYG
1.4 LYG (APACHE ≥ 25)
$ 15,801/LYG $ 10,833/LYG (APACHE ≥ 
25)
Riou França et al. [35]
France (2006)
$7,545 (all patients)
$7,333 (2 organ 
dysfunctions)
0.64 LYG (all patients)
0.57 (2 organ dysfunctions)
$ 11,812/LYG $12,942/LYG (2 organ 
dysfunctions)
Hjelmgren et al [36]
Sweden (2005)
$12,272 (all patients)
$14,663 (≥ 2 organ 
dysfunctions)
0.544 LYG
0.474 LYG (≥ 2 organ 
dysfunctions)
US$ 22,920/LYG $ 30,853/LYG (≥ 2 organ 
dysfunctions)
Davies et al. [37]
UK (2005)
Using PROWESS data
$9,517 1.12 LYG US$ 8,533/LYG -
Green et al. [42]
UK (2006)
$11,645 (SD $1,098) (all 
patients)
$12,336 (SD $1,430) (≥ 2 
organ dysfunctions)
1.144 LYG (SD 0.34)
1.351 LYG (≥ 2 organ 
dysfunctions)
$ 10,176/LYG $ 9,132/LYG (≥ 2 organ 
dysfunctions)
LYG = life-year gained/SD = standard deviation/TA = technology assessment
*Results comparing drotrecogin alfa to placebo
** $/LYG not available.
Table 4: Cumulative survival parameter estimates with all patients with severe sepsis
Drotrecogin alfa
Cumulative survival PROWESS ADDRESS Point estimate Pooled results 
(± SD)
28-day 75.3% [13] 81.5% [14] 79.4% (± 1.06)
Hospital discharge 70.3% [8] 79.4% [14] 76.4% (± 1.11)
3-month 66.1% [8] NA 66.1% (± 1.86)
6-month 62.2% [8] NA 62.2% (± 1.97)
12-month 58.9% [8] NA 58.9% (± 2.05)
30-month 52.6% [8] NA 52.6%(± 2.10)
Placebo
Cumulative survival PROWESS ADDRESS Pooled results (± SD)
28-day 69.2% [13] 83% [14] 78.8% (± 1.04)
Hospital discharge 65.1% [8] 79.5% [14] 74.95% (± 1.12)
3-month 62.4% [8] NA 62.4% (± 1.93)
6-month 60.3% [8] NA 60.3% (± 1.98)
12-month 57.2% [8] NA 57.2% (± 2.06)
30-month 49.3% [8] NA 49.3% (± 2.10)
CI = confidence interval/NA = not available/SA = sensitivity analysis/SD = standard deviationBMC Anesthesiology 2007, 7:5 http://www.biomedcentral.com/1471-2253/7/5
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two previous meta-analyses [31,32]. While much clinical
attention has been previously focused on the mortality
benefit seen in the PROWESS APACHE II ≥ 25 subgroup,
our analysis shows that when the totality of the evidence
is examined uncertainty exists as to this benefit. Support-
ing this conclusion is the lack of benefit in the high risk
group when assessed by a different measure (≥ 2 organs
dysfunction) and diminishing benefits over time. Due to
the difficulties in determining the APACHE II scores [15],
the European Union regulatory authorities have preferred
multiple organ dysfunction as a measure of disease sever-
ity and for labeling indications [43]. Other investigators
have also failed to demonstrate any survival advantage
with drotrecogin alfa at hospital discharge in other high
risk groups, including the need for vasopressor support,
APACHE II score between 30 and 53, and protein C defi-
ciency [28]. The multiple subgroup analyses, both pre-
specified and not, of the PROWESS data [17-30] increases
the possibility that the APACHE II subgroup results may
represent a false positive finding.
In contrast to our results, a company-sponsored meta-
analysis has reported a statistically significant reduction in
the 28-day all-cause mortality in all patients with drotrec-
ogin alfa compared to placebo [33]. However, this
included studies involving indirect comparisons with dif-
ferent sepsis drugs and without contemporaneous con-
trols [33]. Variations in patient entry criteria, treatments
Table 6: Cost estimates used in the decision analytic models. Costs in US dollars.
Costs Model with all patients Model in patients with APACHE 
II score >= 25
Source
Drug costs * (drotrecogin alfa) $9,700 $9,700 MUHC (Pharmacy department)
Bleeding episode costs $12,090 $12,090 Manns et al [40]
Hospitalization costs (severe sepsis episode) $47,960 $51,095 Manns et al. [40]
1-year costs (after hospital discharge)** $20,641 $29,879 Manns et al. [40]
Year 2 costs** $6,641 $8,083 Manns et al. [40]
Year 3 costs** $6,290 $5,762 Manns et al. [40]
* Drug costs refer to acquisition costs of drotrecogin alfa and were therefore used only in this group. Other costs were assumed to be identical in 
both groups.
Costs from the article by Manns et al. [40] were converted to Canadian dollars according to the exchange rate used in the article (US$1 = 
CDN$1.47) and adjusted for inflation according to Bank of Canada rates.
** Costs with 3% discounting
This included direct health care costs for hospitalizations, emergency visits, day surgeries, and physicians' costs [40].
Table 5: Cumulative survival parameter estimates in patients with APACHE II >= 25
Drotrecogin alfa
Cumulative survival PROWESS ADDRESS Point estimate Pooled results 
(± SD)
28-day 69.1% [2] 70.5%[14] 69.45% (± 3.55)
3-month 58.9% [8] NA 58.9% (± 2.42)
6-month 55.2% [8] NA 55.2% (± 2.44)
12-month 52.1% [8] NA 52.1% (± 2.46)
30-month 45.6% [8] NA 45.6% (± 2.45)
Placebo
Cumulative survival PROWESS ADDRESS Pooled results (± SD)
28-day 56.3% [2] 75.3% [14] 62.93% (± 3.40)
3-month 48.4% [8] NA 48.4% (± 2.49)
6-month 45.3% [8] NA 45.3% (± 2.48)
12-month 41.3% [8] NA 41.3% (± 2.45)
30-month 33.8% [8] NA 33.8% (± 2.36)
CI = confidence interval/NA = not available/SA = sensitivity analysis/SD = standard deviation
* Calculated according to the information provided in the studies.BMC Anesthesiology 2007, 7:5 http://www.biomedcentral.com/1471-2253/7/5
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received, lack of randomization, residual confounding
and the potential for calendar time bias undermines the
validity of these results.
Our economic analyses showed that drotrecogin alfa may
not be cost-effective in all sepsis patients due to uncertain-
ties in the survival benefits when all available evidence is
considered. Our economic conclusions differ from most
previous publications, which have assumed that the large
28-day mortality advantage in PROWESS would be sus-
tained and which has not been confirmed either in a long
term follow-up or in another RCT. Our conservative esti-
mate of cost-effectiveness, while in contradiction to other
published analyses, nevertheless more adequately models
the known long-term efficacy data for this drug.
Although the cost effectiveness of drotrecogin alfa
improves when restricted to treating those at the highest
risk, caution must be exercised in attempting to justify
treatment only to a specific subgroup. Severe sepsis is a
very complex syndrome [44], therefore, even in the RCTs
it cannot be ruled out that some of the multiple measured
and unmeasured baseline confounders may be unequally
balanced with repeated subgroup analyses. Basing treat-
ment on disease severity is problematic for several other
reasons; not the least that the pooled data do not show a
statistical benefit for very high risk, whether assessed by
APACHE II or multiple organ failure score; second,
APACHE II does not take into account important meas-
ures of severity in severe sepsis patients such as white
blood cell count, number of days in hospital and ICU
before the diagnosis of severe sepsis. [15].
The main limitation of our economic analyses centers on
the uncertain estimate of clinical efficacy. While this been
approached systematically the short term results are
derived from only 2 trials with evidence of statistical het-
erogeneity between them and the long term results come
from a single study. However as we have argued, the clin-
ical similarities between the patient populations as well as
the standardized active therapy suggests that the best esti-
mate of clinical efficacy arises from the pooled estimate.
Moreover the robustness of our model in different sensi-
tivity analyses provides further assurance.
Table 7: Incremental effectiveness and costs from our base-case analyses (drotrecogin alfa compared to placebo)
Model Incremental Cost (95% CI) Incremental effectiveness (LYG) % simulations where drotrecogin alfa has a lower effectiveness than 
placebo
All patients $11,024
($8,670, $13,341)
0.344
(-0.807, 1.476)
27%
APACHE II ≥ 25 $13,612
($9,785, $17,421)
1.191
(-0.082, 2.417)
3%
CI = confidence interval
LYG = life-years gained
Cost-effectiveness plane for all patients – 10,000 Monte  Carlo simulations (20-year time horizon, 3% discounting) Figure 4
Cost-effectiveness plane for all patients – 10,000 
Monte Carlo simulations (20-year time horizon, 3% 
discounting). The points to the left of the vertical line cor-
respond to a lower efficacy and higher cost with drotrecogin 
alfa compared to placebo.
Incremental Cost/LYG (All patients)
Drotrecogin alfa compared to Placebo
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Cost-effectiveness plane for patients with APACHE II ≥ 25 –  10,000 Monte Carlo simulations (20-year time horizon, 3%  discounting) Figure 5
Cost-effectiveness plane for patients with APACHE 
II ≥ 25 – 10,000 Monte Carlo simulations (20-year 
time horizon, 3% discounting). The points to the left of 
the vertical line correspond to a lower efficacy and higher 
cost with drotrecogin alfa compared to placebo.
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Conclusion
The debate on the place of drotrecogin alfa persists as
judged by the numerous recently published editorials and
comments [6,7,43,45-58]. Hopefully our systematic and
transparent economic model will assist clinicians and
decision makers in assessing the current efficacy of drot-
recogin alfa and its cost-effectiveness. At present, our anal-
ysis does not support the cost-effectiveness of drotrecogin
alfa in all severe sepsis patients but suggests that a targeted
approach to the very high risk patients may be appropriate
while awaiting additional evidence.
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